Perceptive Advisors’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Perceptive Advisors’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-173,365	Closed	-$971K	–	125
2024 Q2	$971K	Buy	+173,365	New	+$755K	0.02%	101
2017 Q3	–	Sell	-100,000	Closed	-$7.89M	–	156
2017 Q2	$7.89M	Buy	+100,000	New	+$8.18M	0.4%	55
2017 Q1	–	Sell	-498,198	Closed	-$39.5M	–	207
2016 Q4	$39.5M	Sell	498,198 -46,572	-9%	-$3.38M	2.81%	10
2016 Q3	$3K	Buy	544,770 +244,770	+82%	+$13.6M	﹤0.01%	188
2016 Q2	$11.6M	Buy	300,000 +112,785	+60%	+$4.7M	0.81%	27
2016 Q1	$7.58M	Buy	187,215 +54,070	+41%	+$3.43M	0.67%	39
2015 Q4	$11.8M	Buy	133,145 +10,101	+8%	+$798K	0.87%	31
2015 Q3	$9.11M	Sell	123,044 -110,000	-47%	-$9.15M	0.73%	34
2015 Q2	$18.8M	Buy	233,044 +220,956	+1,828%	+$14.4M	1.13%	21
2015 Q1	$506K	Buy	+12,088	New	+$343K	0.04%	115

Other funds holding EGRX

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Perceptive Advisors's EGRX Position: Q3 2024 in Review

Perceptive Advisors sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2024, closing a stake of 173,365 shares — an estimated $971K sold.

Perceptive Advisors first reported a position in EGRX in Q1 2015 and held it in 10 quarters. The position peaked at $39.5M in Q4 2016. 65 funds tracked by Wall St. Rank hold EGRX as of Q3 2024.

Perceptive Advisors reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2024 after selling out during the quarter.
Perceptive Advisors sold 173,365 Eagle Pharmaceuticals, Inc. shares in Q3 2024, an estimated $971K.
Perceptive Advisors first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2015 and held it in 10 quarters.
Perceptive Advisors's Eagle Pharmaceuticals, Inc. position peaked at $39.5M in Q4 2016.
65 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2024.

Based on Perceptive Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.